Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6897801 | 1.00 | FAAH (0.41) | FAAHL3MBTL1CA2NPC1TSHR | |
| SCHEMBL1069645 | 0.96 | FAAH (0.41) | FAAHL3MBTL1CA2NPC1TSHR | |
| SCHEMBL6901401 | 0.96 | FAAH (0.41) | FAAHL3MBTL1CA2NPC1TSHR | |
| SCHEMBL24767441 | 0.94 | FAAH (0.45) | FAAHL3MBTL1CA2TSHRMAPK1 | |
| SCHEMBL2817480 | 0.94 | L3MBTL1 (0.42) | FAAHL3MBTL1CA2TSHRMAPK1 | |
| SCHEMBL6894873 | 0.94 | L3MBTL1 (0.42) | FAAHL3MBTL1CA2TSHRMAPK1 | |
| SCHEMBL18937755 | 0.92 | FAAH (0.43) | FAAHL3MBTL1CA2TSHRMAPK1 | |
| SCHEMBL7863051 | 0.92 | FAAH (0.43) | FAAHL3MBTL1CA2TSHRMAPK1 | |
| SCHEMBL10722736 | 0.89 | FAAH (0.48) | FAAHL3MBTL1CA2ALDH1A1GAA | |
| SCHEMBL7122564 | 0.89 | FAAH (0.48) | FAAHL3MBTL1CA2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734311-B2 | ANTIINFLAMMATORY AGENTS; ALZHEIMER'S DISEASE; CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2004-05-11 | — | — | US | disclosed |
| US-20030092746-A1 | Substituted amidine derivatives as inhibitors of cell adhesion | MERCK & CO., INC. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092746-A1 | Substituted amidine derivatives as inhibitors of cell adhesion | VCAM1, CD4, ICAM1 | FAAH 795/4885L3MBTL1 2016/4885CA2 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.